On April 7, 2023, Shandong Sito Bio-technology Co., Ltd. closed the transaction. The company has now issued 11,641,762 common shares at a price of CNY 22.47 per share for the gross proceeds of CNY 261,590,392.14. The company has paid issue fees of CNY 9,667,983.99.

The transaction included participation from new investors, Nuode Asset Management Co., Ltd. for 1,659,987 shares for CNY 37,299,907.89, Caitong Fund Management Co., Ltd. for 2,599,010 shares for CNY 58,399,754.70, Li Lifeng for 890,075 shares for CNY 19,999,985.25, Jintai Longsheng No.1 Private Securities Investment Fund for 445,037 shares for CNY 9,999,981.39, Beijing Chuangfu Jintai Investment Fund Management Co., Ltd, Jintai Jixiang No. 1 Private Securities Investment Fund for 445,037 shares for CNY 9,999,981.39, Zhang Jianfei 1,246,105 shares for CNY 27,999,979.35, Fanyi Private Placement Choice No. 1 Private Securities Investment Fund, Qingdao Fanyi Asset Management Co., Ltd. for 445,037 shares for CNY 9,999,981.39, China Asset Management Co.

Ltd. for 1,023,587 shares for CNY 22,999,999.89, Xu Guoxin 1,424,121 shares for CNY 31,999,998.87, Danyin Preferred No. 2 Private Securities Investment Fund, Shanghai Danyin Investment Management Center (limited partnership) for 534,045 shares for CNY 11,999,991.15, Zhixing Lita Rongyou Wenjian Phase I Private Equity Securities Investment Fund, Zhixing Lita Private Fund Management (Beijing) Co., Ltd. for 929,721 shares for CNY 20,890,830.87. Prior to issuance, Li Lifeng owns 1.58 million shares in the company, accounting for 1.48% stake.

Post issuance, Caitong Fund Management Co., Ltd. owns 2,599,010 shares in the company, accounting for 2.19% stake, Li Lifeng owns 2,470,075 shares, accounting for 2.08% stake and Nuode Asset Management Co., Ltd. owns 1,659,987 shares, accounting for 1.40% stake.